logo-loader
RNS
ValiRx PLC

ValiRx PLC - Material Transfer Agreement

RNS Number : 6361L
ValiRx PLC
01 May 2020
 

 

 

 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

 

MATERIAL TRANSFER AGREEMENT WITH JAPANESE PHARMACEUTICAL COMPANY

 

London, UK., 1 May 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that it has signed an agreement with a global Japanese pharmaceutical company to evaluate Valirx's therapeutic, VAL301, for the purpose to contemplate a potential future license, for its use in the treatment of endometriosis.

 

The Material Transfer Agreement ("MTA") covers the evaluation of VAL 301 in a series of preclinical proof of concept and efficacy studies relating to endometriosis.  Studies are also scheduled to consider proprietary delivery methods for the compound.

 

The Japanese Company has already conducted a thorough review of Valirx's prior data under terms of a confidentiality agreement, and now wishes to use material provided by Valirx to conduct their own experiments.

 

By way of context, ValiRx has developed its VAL301 decapeptide for use in the treatment of endometriosis, while the Japanese Company has a range of pre-clinical assays for testing drug candidates for use in the treatment of endometriosis, as well as several commercial and developmental products in women's health, and other healthcare areas.

 

To both parties' mutual potential benefit therefore and under the terms of the MTA, ValiRx will supply the required quantities of compound, while the Japanese sponsor will be responsible for undertaking an agreed programme of work at its own expense.

 

-ENDS-

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

 

For more information, please contact:

 

ValiRx plc

Tel: +44 (0) 20 7073 2628

www.valirx.com

Kevin Alexander


Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

Tel: +44 (0) 20 7213 0880

Peterhouse Capital Limited (Sole Broker)

Duncan Vasey / Lucy Williams / Eran Zucker

 

Tel: +44 (0) 20 7469 0930

Notes for Editors

 

About VAL301

VAL301 is derived from ValiRx's lead compound and is currently in late-stage pre-clinical development as a non-invasive, effective treatment for the hugely debilitating gynaecological condition, endometriosis. ValiRx has established from its pre-clinical studies that VAL301's specific mode of action has the potential to provide a potent therapeutic effect to manage the symptoms of endometriosis, without side effects, including loss of bone density and/or infertility.

 

About Endometriosis

Endometriosis is a benign, oestrogen -dependent chronic condition, characterised by endometrial tissue growth outside of the uterus.  Symptoms including heavy painful periods, pain with intercourse and infertility are often severe and are associated with a decreased quality of life for young women. The condition affects an estimated 1 in 10 women during their reproductive years, equating to approximately 176 million women worldwide*, posing a high economic burden.

 

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

 

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

 

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College. 

 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRMZGGKNMDGGZG
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read